This study was presented in part at the 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24–28, 2001, and the 23rd Annual Meeting of the American Society for Bone and Mineral Research in Phoenix, AZ, October 12–16, 2001
Article first published online: 1 FEB 2003
Copyright © 2003 ASBMR
Journal of Bone and Mineral Research
Volume 18, Issue 2, pages 222–230, February 2003
How to Cite
Brubaker, K., Vessella, R., True, L., Thomas, R. and Corey, E. (2003), Cathepsin K mRNA and Protein Expression in Prostate Cancer Progression. J Bone Miner Res, 18: 222–230. doi: 10.1359/jbmr.2003.18.2.222
The authors have no conflict of interest
- Issue published online: 2 DEC 2009
- Article first published online: 1 FEB 2003
- Manuscript Accepted: 16 AUG 2002
- Manuscript Revised: 29 JUL 2002
- Manuscript Received: 27 FEB 2002
- cathepsin K;
- prostate cancer;
- bone metastases;
- cysteine proteases
Prostate cancer (CaP) is the most commonly diagnosed malignancy in men and is often associated with bone metastases, which cause much of the morbidity associated with CaP. Lesions associated with CaP generally exhibit increased bone formation and resorption. Increased bone resorption may release factors from the extracellular matrix that contribute to tumor growth. Cathepsin K (cat K) is a cysteine protease that exhibits strong degradative activity against the extracellular matrix and is involved in osteoclast-mediated bone destruction. In this study, we analyzed the expression of cat K in CaP cell lines and patient samples. Cat K message was detected in CaP cell lines by reverse transcription-polymerase chain reaction (RT-PCR) and in primary CaP and metastases by in situ hybridization. Immunohistochemistry revealed variable expression of cat K in primary CaP samples, as well as nonosseous metastases, whereas expression in bone metastases was significantly higher than in primary CaP, and normal prostate tissues were negative. Cat K protein was detected in CaP cell lines by Western blotting after immunoprecipitation. Cat K enzymatic activity was also detected in CaP cell lines by a fluorogenic assay and by an assay for degradation of collagen type I. Increased levels of NTx, a marker of bone matrix degradation mediated primarily by cat K, were also detected in sera of patients with CaP bone metastases. We hypothesize that CaP-expressed cat K may contribute to the invasive potential of CaP, while increased expression in bone metastases is consistent with a role in matrix degradation.
BONE IS THE second most common site of metastasis (after lymph nodes) for prostate cancer (CaP). Although most CaP bone metastases are considered osteoblastic, based on patterns observed on radiographs, there is evidence that markers of bone resorption are elevated in patients with CaP bone lesions.(1–3) Detailed studies of bone metastases using histomorphometry have also demonstrated that radiographically sclerotic lesions exhibit both bone formation and resorption.(4–7) Recently it has been established that various cancers, including breast and prostate, support osteoclastogenesis through expression of the receptor activator of NF-kB ligand (RANKL),(8–10) providing one possible mechanism to explain the increased bone resorption observed with bone metastases. In addition to supporting osteoclast formation, it has been demonstrated that CaP expresses proteases that degrade matrix proteins, representing another potential mechanism of increased bone matrix degradation associated with bone metastases. In 1998, Sanchez-Sweatman et al.(11) reported that a CaP cell line, PC-3, degrades bone extracellular matrix and mineralized bone in vitro by secreting matrix metalloproteinases (MMPs). Nemeth et al.(12) demonstrated that MMP inhibitors prevented bone degradation in a PC-3-human bone-SCID mouse model. They observed that PC-3 tumors expressed MMPs in vivo, raising the possibility that the tumor cells participate in the process of bone turnover through expression of proteases.
Cathepsin K (cat K) is a cysteine protease secreted by osteoclasts that degrades extracellular matrix during bone resorption. Its significance in bone remodeling is demonstrated by the osteopetrotic phenotype observed in knockout studies.(13) Cat K has one of the highest matrix degradation activities known, cleaving type I collagen with higher efficiency than other cathepsins and MMPs, and its elastinolytic activity is higher than that of cat L and pancreatic elastase.(14, 15) Because of its ability to destroy matrix components efficiently, cat K and some of its family members have been implicated in diseases involving bone and cartilage destruction, including tumor invasion(16–19) and rheumatoid arthritis.(20, 21)
While its proteolytic activity is strongest at low pHs as in the lacunae of osteoclasts,(22) cat K can also degrade extracellular matrix components at neutral pHs, suggesting a general role in tissue destruction and remodeling.(23) In addition to the strong expression observed in osteoclasts, cat K protein has been detected in breast cancer,(24) sites of granulomatous inflammation,(25) human lung,(26) thyroid epithelial cells,(27) human endometrium,(28) and mouse ovary.(29)
In this study, we report detection of cat K message and protein in samples representing various stages of CaP progression and show that cat K expressed by CaP cells possesses enzymatic activity. Our data suggest that cat K derived from CaP cells may play a role in tumor invasiveness and extracellular bone matrix degradation.
MATERIALS AND METHODS
CaP cell lines, DU 145, PC-3, B-PC-3, N-PC-3, LNCaP, C4, and C4–2 were cultured in RPMI-1640 medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% FBS (Life Technologies) at 37°C under standard conditions. Murine osteoclasts were generated from bone marrow of Balb/c mice (Charles River, Hollister, CA, USA) as follows. Femur marrow cavities were flushed five to six times with phenol red-free MEM (Life Technologies), and cells were centrifuged at 500g and plated at a density of 1 × 106 cells per 9.6 cm2 well. Cells were cultured in MEM supplemented with 2% FBS, 30 ng/ml colony-stimulating factor-1 (CSF-1; R&D Systems, Minneapolis, MN, USA), and 50 ng/ml RANKL (Chemicon, Temecula, CA, USA) for 5–6 days. Media was replaced every third day of culture. Osteoclast formation was confirmed by detection of TRACP+ multinucleated cells (TRACP assay, Sigma, St. Louis, MO, USA) after 5–6 days in culture, and the appearance of resorptive activity on dentine wafers (Immunodiagnostic Systems Ltd., Boldon, UK).
Human prostate tissue samples used in this study were obtained from organ donors (n = 2), radical prostatectomies (n = 16), or rapid autopsies (n = 14). Tissues were fixed in 10% buffered formalin and embedded in paraffin. Bone samples were fixed in formalin and decalcified in 5% formic acid before embedding. Five-micrometer sections were used for immunohistochemistry (IHC) and in situ hybridization (ISH). Slides were baked at 60°C overnight before deparaffinization in xylene (×3) and rehydration in a series of 100%, 95%, and 70% ethanol (EtOH) rinses. Tissue integrity was assessed by hematoxylin and eosin staining, and the presence of CaP cells was assessed by prostate specific antigen (PSA) staining.
Total RNA was isolated from CaP cell lines using STAT 60 (Tel-Test, Friendswood, TX, USA) according to the manufacturer's instructions. cDNA was generated from 1 μg total RNA using Moloney murine leukemia virus (MMLV) reverse transcriptase (Clontech, Palo Alto, CA, USA) with random hexamers. A 399-bp fragment of cat K (bps 906–1305, accession no. X82153) was amplified using primers: 5′-CAGCAAAGGTGTGTATTATGATGAAAGC and 3′-ATGGGTGGAGAGAAGCAAAGTAGGAAGG. Beta2-microglobulin cDNA was amplified as a control for RNA quality, and polymerase chain reaction (PCR) conditions were as previously reported(30): 1 cycle at 80°C for 3 minutes, and then 30–35 cycles of 94°C for 10 s, 69°C for 1 minute, and a final extension period at 72°C for 7 minutes.
The 399-bp amplicon of cat K was cloned into the pGEM-T vector (Promega, Madison, WI, USA). DNA sequencing was used to confirm the identity and determine the orientation of the insert. Purified plasmid was linearized using either NcoI or NotI and digoxigenin-labeled anti-sense and sense riboprobes were generated using a T7 and SP6 in vitro transcription kit (Roche, Indianapolis, IN, USA). The probes were separated on a 1.2% agarose gel, and relative amounts of RNA were quantified using a digital image analyzer (Alpha Innotech Corp., San Leandro, CA, USA). ISH was performed using the Ventana genII automated ISH system (Ventana Medical Systems, Tuscon, AZ, USA). Hybridization was performed using 25 ng/slide sense or anti-sense riboprobes at 45°C for 5 h in hybridization buffer (8 mM Tris, pH 8.0, 50% deionized formamide, 10% dextran sulfate, 1× Denhardt's solution, 0.3 M NaCl, 0.8 mM EDTA, 2 mg/ml yeast tRNA, 10.0 mM DTT), with subsequent rinses of 2×, 1×, 1× SSC buffer at 45°C. An anti-digoxigenin monoclonal antibody (1:2000; Sigma) was used with biotinylated rabbit anti-mouse antibodies, streptavidin-horseradish peroxidase (HRP), and diaminobenzidine (DAB) as the substrate. Sections were counterstained with Harris' hematoxylin before mounting.
Endogenous peroxidase was quenched by incubation of tissues in 0.3% hydrogen peroxide in PBS for 10 minutes. Nonspecific binding was blocked with serum block (5% goat, 5% horse, 5% rabbit sera) in PBS for 1 h at room temperature. Endogenous biotin was blocked using an avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA, USA). An affinity purified chicken antibody against human cat K (Immunodiagnostic Systems Ltd.) was applied at 40 ng/ml, and the sections were incubated overnight at 4°C in a humidified chamber. Negative control sections were incubated with isotype-matched chicken IgY (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Sections were incubated with biotin-conjugated rabbit anti-chicken antibodies (1:250, Chemicon) for 30 minutes at room temperature and processed with an ABC kit (Vector Laboratories) with DAB. Sections were counterstained in Harris hematoxylin and blue in ammonia water before mounting. Giant cell tumor tissues were used as a positive control for cat K staining.
Statistics for IHC samples
The percentage of cat K-positive cells in tissues was assessed as 0%, 1–25%, 25–50%, 50–75%, or 75–100% by a pathologist, who was blinded to the samples, and assigned values of 0, 1, 2, 3, or 4, respectively. Immunoreactivity in primary CaP and nonosseous and osseous metastases were compared using a one-way ANOVA with a Bonferroni's comparison posttest.
Immunoprecipitation of cat K
Approximately 500 μg CaP tissue or 5 × 106 LNCaP or PC-3 cells were homogenized in 1.0 ml lysis buffer (10 mM Tris, pH 7.4, 50 mM NaCl, 0.25% Triton X-100, 0.25% sodium deoxycholate, 0.5% CHAPS, and Complete protease inhibitors) and centrifuged for 20 minutes at 14,000 rpm before immunoprecipitation. Cat K protein was immunoprecipitated overnight at 4°C using a mixture of mouse monoclonal anti-cat K antibodies CP1A240.2 and CP1K338.4 (0.25 mg each, a gift from Beckman Coulter Inc., Fullerton, CA, USA), which were bound to protein G Sepharose beads (Pierce, Rockford, IL, USA). After extensive washes to release unbound proteins, cat K was eluted from the column as recommended by the manufacturer. The eluted protein was separated on a 15% SDS-PAGE gel and transferred to polyvinylidene difluoride (PVDF) at 100 V for 1 h. Cat K protein was detected using a mouse monoclonal antibody CP1A713 (0.25 μg/ml, a gift from Beckman Coulter Inc.). MOPC21 (Sigma), an unrelated mouse monoclonal antibody, was used as a negative control. Blots were incubated with goat anti-mouse-HRP conjugated secondary (1:3000; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) antibody and Amersham ECL (Piscataway, NJ, USA) was used for detection with Kodak X-OMAT AR film (Rochester, NY, USA).
Cleavage of Z-GPR-MCA
After tissue culture (see above) CaP cells (∼1–3 × 106) or osteoclasts (Oc, ∼105) were lysed in 1.0 ml assay buffer (50 mM sodium acetate, pH 5.5, 2.5 mM dithiothreitol and 2.5 mM EDTA) on ice containing 1.0% Triton X-100. Protein levels were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA). One hundred microliters lysate (corresponding to 150–200 μg protein for CaP cell lines and 5–10 μg for osteoclasts) was added to 400 μl assay buffer, or buffer containing either a general cysteine protease inhibitor E64 (L-trans-epoxy-succinyl-Leu-4-guanidinobutylamide; Calbiochem, San Diego, CA, USA) or a cathepsin B inhibitor, CA 074 (L-trans-epoxy-succinyl-Ile-Pro-OH propylamide; Calbiochem). Reaction tubes were incubated for 30 minutes at room temperature before the addition of 10 μl of 4 × 10−3 M Z-GPR-MCA (benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin, 80 μM final concentration; Bachem, King of Prussia, PA, USA). The reactions were placed at 37°C (10 minutes for Oc, 30 minutes for LNCaP and DU 145, and 75 minutes for PC-3) and terminated by addition of 500 μl of stopping reagent (100 mM sodium monochloroacetate, 30 mM sodium acetate, 70 mM acetic acid, pH 4.3). Cleavage of the substrate was measured by the fluorescent emission of the free aminomethylcoumarin at 470 nm (excitation, 360 nm). A standard curve was generated with 7-amino-4-methylcoumarin (0.01–5 μM) to calculate the amount of coumarin released. Human liver cathepsin B (200 ng, Calbiochem) was used to determine the dose response to CA 074.
Type I collagen degradation assay
Lysates from PC-3, LNCaP, DU 145, and osteoclasts (200 μl total volume, 150 μg protein; 10 μg for Oc), prepared in the same assay buffer used in the Z-GPR-MCA experiments, were added to wells in a 96-well plate coated with 1.2 μg/ml purified rat type I N-[propionate-2,3-3H]propionylated collagen (NEN Life Science Products, Boston, MA, USA). After a 6-h incubation at 37°C, 75 μl of the reaction was collected, 3 ml CytoScint scintillation cocktail (ICN, Costa Mesa, CA, USA) was added, and release of degradation products of collagen was measured using a Beckman LS-3801 beta spectrometer (Beckman Coulter Inc.). Lysates were also treated with E64 (1 μM) to inhibit cysteine protease activity. Samples were run in triplicate in three separate experiments. The experimental data are presented as the mean ± SEM of the three sets, which have been normalized to the maximum signal strength. Statistical significance between untreated and 1-μM E64 samples was determined by unpaired t-tests.
Bone resorption pit assay
LNCaP and PC-3 (50,000 cells/well) were cultured on dentine wafers (Immunodiagnostic Systems Ltd.) in 24-well plates with 1 ml RPMI 1640 + 10% FBS. Osteoclasts, generated as described in the tissue culture section, were used as a positive control for resorption. After 5–6 days of culture, the media was removed and replaced with 1 M NH4OH for 30 minutes. The dentine wafers were then cleaned by ultrasonication for 30 minutes and stained with hematoxylin (Zymed, South San Francisco, CA, USA) for 1 minute and washed with distilled water. Resorption pits were visualized under transmitted light.
N-telopeptides of type I collagen ELISA
Cross linked N-telopeptides of type I collagen (NTx) were measured in serum samples from CaP patients using the Osteomark assay kit (Ostex International Inc., Seattle, WA, USA). Serum samples were obtained from 10 donors (mean PSA = 1.09 ± 0.16); 10 patients with organ-confined CaP, stages T2a-c or T1c (mean PSA = 7.43 ± 1.16); 5 patients with bone metastases who had not received any treatment (mean PSA = 557.6 ± 173.3); 8 patients with bone metastases who had received one or more treatments for CaP, including androgen ablation, chemotherapy or radiation (mean PSA = 1087 ± 464); and 6 patients who had received bone resorption inhibitors in addition to other treatments listed above (mean PSA = 4097 ± 1729). All patients gave informed consent. The majority of the patients used for this assay were the same patients used in the ISH and IHC studies. NTx levels were compared for statistical significance using a one-way ANOVA with a Bonferroni's comparison posttest.
Expression of cat K mRNA
Cat K mRNA was detected in all CaP cell lines tested, which include the androgen-independent cell lines DU 145 and PC-3, the PC-3 sublines, B-PC-3 and N-PC-3, the androgen-sensitive cell line LNCaP, and its androgen-independent sublines C4 and C4–2 by RT-PCR (Fig. 1). In addition, the presence of cat K mRNA was assessed in 2 samples of normal prostate from organ donors, 7 localized CaP tumors, and 25 metastatic samples from 7 patients by ISH. ISH demonstrated the presence of cat K mRNA in epithelial cells of primary CaP in 5 of 7 samples (Fig. 2A), while a moderate signal was observed in basal and luminal cells of normal glands (3/7, Fig. 2A, arrow) adjacent to the cancer. Samples of normal prostate from organ donors were negative. Cat K mRNA was detected in nonosseous metastases including liver (2/2), lymph node (2/3, Fig. 2B), and lung (1/1), and 15/19 osseous CaP metastases (Fig. 2C). When present, osteoclasts were intensely positive for cat K message. Cat K mRNA was not observed in stromal fibroblasts, stromal smooth muscle, or vascular smooth muscle. Staining with the sense probe was negative (Figs. 2D–2F).
Cat K protein expression in CaP
The presence of cat K protein was assessed in 14 samples of localized CaP and in 52 metastases from 14 patients. Immunohistochemistry revealed the presence of cat K protein in the epithelial cells of cancerous glands in 6/14 primary CaP samples (Fig. 3A). Normal glands adjacent to CaP were negative. Cat K protein was also detected in metastases to liver (3/4), lung (3/3), adrenal (1/1), and lymph node (4/10, Fig. 3B); however the immunoreactivity in these samples was variable, ranging from no staining to 100% positivity. Osseous metastases were positive for cat K protein expression in 30/34 samples (Fig. 3C). Intense immunoreactivity for cat K was observed in osteoclasts in CaP bone metastases (Fig. 3C, arrow). A giant cell tumor was used as the positive control for cat K staining (Fig. 3D). Table 1 summarizes IHC results for metastases from nine patients in which multiple metastatic sites were evaluated. The percentage of tumor cells exhibiting cat K immunoreactivity in osseous metastases was significantly higher than in primary CaP (p < 0.05) and nonosseous (p < 0.001) samples. The percentages of tumor cells exhibiting cat K immunoreactivity in primary CaP versus nonosseous metastases were not significantly different (p > 0.05).
To confirm the presence of cat K protein in CaP, we performed Western blot analysis of cell lysates from CaP cell lines LNCaP and PC-3, and CaP tissues that were positive by IHC. We were unable to detect the cat K protein under these conditions. Therefore, we immunoprecipitated cat K from CaP cells lines and CaP tissues to obtain more concentrated samples. After this, a 40-kDa band was labeled in blots from CaP tissues (Fig. 4A, arrow) and LNCaP and PC-3 cell lines (Fig. 4B, arrow). The 40-kDa protein is most likely the proform of cat K.(23, 31) The light chain band in Fig. 4B would be expected to mask the active form of cat K band at 28 kDa, but when non-denaturing gels were run as in Fig. 4A, we still did not observe a band at 28 kDa.
Cat K enzymatic activity
The presence of cat K enzymatic activity in CaP cells was evaluated using Z-GPR-MCA, a substrate that is highly selective for cat K versus cathepsins L and S.(23, 31) Z-GPR-MCA cleavage activity was detected in LNCaP, PC-3, and DU 145 cell lines (Table 2). Because cathepsin B (cat B) also cleaves Z-GPR-MCA, but at a much lower rate, the portion of the activity caused by cat B was determined using the cat B inhibitor CA 074. CA 074 blocked approximately 75% of the activity in LNCaP and DU 145, and 50% of the activity in PC-3. The remaining activity was inhibited by a general cysteine protease inhibitor, E64, suggesting that it was caused by cat K. For inhibition of cat B activity, we used 50 nM CA 074, a concentration determined from dose-response experiments. Fifty nanomolar CA 074 inhibited purified human cat B activity with the Z-GPR-MCA substrate and a specific cat B substrate, Z-RR-MCA (data not shown) as effectively as E64. LNCaP and DU 145 exhibited 2.5- to 3-fold more Z-GPR-MCA cleavage activity than PC-3 after inhibition of cat B. Activity of cat K in osteoclast lysates, which were used as the positive control, was approximately 50-fold higher (normalized to protein) than in the LNCaP and DU 145 CaP cell lines. Because our osteoclast purity was 30–50% as determined by TRAP staining, the cat B activity in this preparation is most likely caused by contaminating mononuclear cells, because osteoclasts express low levels of cat B.(32, 33)
We have also evaluated whether CaP cells exhibit pitting activity using dentine wafers. We were unable to detect pitting capabilities of CaP cells; osteoclasts were used as a positive control (data not shown). Because cat K can degrade type I collagen, we also performed experiments to determine whether CaP cells can degrade collagen. We observed type I collagen-degradation activity in LNCaP, DU 145, and osteoclast lysates under the same assay conditions used in the Z-GPR-MCA assay (Fig. 5). PC-3 lysates were unable to degrade collagen under the conditions used. The general cysteine protease inhibitor E64 blocked approximately 50% of the cleavage activity in LNCaP, DU 145, and osteoclast lysates, confirming that the activity is attributable to cysteine proteases.
NTx levels in sera from CaP patients
Increased type I collagen degradation associated with CaP bone metastases was demonstrated by measuring NTx levels in the sera of patients with either organ-confined CaP or CaP bone metastases (Fig. 6). The levels in patients with bone metastases who received treatment for CaP, including androgen ablation, which has been reported to increase bone resorption,(34, 35) were statistically significant from the normal donors (p < 0.001) and primary CaP (p < 0.01; Table 3). NTx levels in patients with bone metastases who were not treated for CaP were statistically significant from the normal controls (p < 0.05).
In this study, we present data suggesting that cat K, a cysteine protease normally associated with osteoclastic bone resorption, is associated with CaP progression. The presence of cat K in primary CaP is consistent with a possible role in matrix degradation via digestion of type I collagen, before dissociation and dissemination. However, the same enzymatic activity at metastatic sites in the bone may promote establishment of micrometastases and may also lead to release of factors supporting tumor growth.
We observed cat K protein in cancerous glands of approximately 40% of the primary CaP tissues tested, exhibiting no correlation with Gleason score or cancer grade. Although prostate basement membrane consists primarily of type IV collagen(36, 37) and laminin,(38, 39) Burns-Cox et al.(40) observed an increase in type I collagen synthesis and degradation at the cancer foci in biopsy specimens from patients with primary CaP. Enzymes that cleave type I collagen, such as the cathepsins and MMPs, are reported to be upregulated in CaP.(17,41–46) Therefore, cat K may be an important factor at the local level in CaP dissemination. However, we did not detect a significant increase in NTx levels in CaP patients with organ-confined disease versus control samples. A possible explanation is that the levels of cat K and type I collagen in organ-confined CaP are insufficient to cause detectable systemic increases the of NTx levels. In the absence of long-term follow-up information on these patients, it is not possible to determine whether the presence of cat K in the primary tumor is strongly correlated with subsequent metastasis, but it is at least conceivable that this enzyme is important or even essential for dissemination of CaP cells from the primary tumor. This hypothesis is supported by the observation that metastases in general exhibited equal or higher positivity than the primary tumors (41/52).
We also observed higher cat K immunoreactivity in osseous metastases versus nonosseous and primary CaP. This is consistent with the NTx assay results, which demonstrated increased matrix degradation in patients with bone metastases versus normal controls and patients with primary CaP. Type I collagen is the major extracellular matrix component of bone, and there is an extensive body of evidence that type I collagen breakdown products, including NTx, are present at elevated levels in the serum and urine of patients with CaP bone metastases.(1–3,47–49) Increased resorption associated with bone metastases, including CaP bone metastases, is linked to stimulation of osteoclastogenesis through RANKL expression.(8–10) Augmented NTx levels are generally associated with increased osteoclastic bone resorption activity because of cat K expressed by these cells, yet we observed osteoclasts in samples from only 3/14 patients with advanced CaP bone metastases. Although we sample 20 bone sites per patient, it is possible that we missed areas with extensive bone resorption and osteoclasts. Alternatively, the increased NTx levels may be in part because of the breakdown of type I collagen by cells other than osteoclasts, such as the CaP cells expressing cat K.
Detection of cat K mRNA and protein in CaP tissues and cell lines led us to determine whether the enzyme was catalytically active. We observed that LNCaP and DU 145 had 2.5- to 3-fold more activity than PC-3, whereas osteoclasts exhibited 50-fold more activity than LNCaP and DU 145 CaP cells in assays of Z-GPR-MCA cleavage. We also determined that LNCaP and DU 145 lysates exhibit type I collagen-degradation activity, whereas PC-3 do not. When CaP cells were plated on labeled collagen or dentine wafers, cleavage activity was not detected, although osteoclasts exhibited activity. Our activity data suggest that CaP cell lines in vitro express low levels of cat K, which seem not to be active in culture but can be activated at a low pH in lysates. The low levels of cat K activity in CaP cells correlated with our Western blotting/immunoprecipitation results: we detected a faint 40-kDa protein, corresponding to the proform of the enzyme.(23, 31) We were unable to detect the 28-kDa active form of cat K, possibly because the quantity immunoprecipitated was below the level of detection. In addition, the presence of cystatins, natural inhibitors of the cathepsins, in CaP cell lines may also contribute to the low activity observed or difficulty in immunoprecipitation.(50) It is intriguing that PC-3 cells had lower levels of cat K activity than LNCaP, because PC-3 metastases in bone are osteolytic,(12, 51) whereas LNCaP lesions exhibit both bone formation and resorption.(51) PC-3 express MMPs,(12) urokinase plasminogen activator,(52) RANKL,(53) endothelin-1,(54) and PTHrP(55)—factors involved in metastases to bone and bone remodeling. The formation of PC-3 osteolytic bone metastases seems to involve a complex set of mechanisms, and cat K may play a very minor role in this case. Moreover, the low cat K activity in CaP cell lines may not be representative of the expression or activity levels in CaP in vivo.
In this study we report our observations of the expression of cat K mRNA and protein in CaP cell lines and tissues, as well as cat K activity in CaP cell lines. The presence of cat K in primary CaP may promote the process of dissemination, whereas in osseous metastases, which exhibit higher levels of markers of bone formation and resorption, cat K is most likely involved in degradation of the extracellular matrix. This process may not only provide sites for CaP cell anchorage, but also cause the release of growth factors essential for tumor growth. Inhibition of cat K activity in vivo using xenograft models may permit a more precise definition of the role of CaP-expressed cat K and yield insight regarding novel therapeutic strategies.
We would like to thank Beckman Coulter Inc. for generously providing us with the three monoclonal antibodies against cat K used in the immunoprecipitation/Western blotting experiments. We would also like to thank Lisha Brown for her expertise in tissue culture and Dr Michael Corey for editorial assistance. Support for this work was provided by National Institutes of Health Training Grant 5T32DK07779–02, NIDDK O'Brien Center Award DK47656–08, U.S. Army DOD DAMD17–00–1–0529, a Merit Review grant from the Department of Veterans Affairs, the Richard M. Lucas Foundation, and the CaPCure Foundation.
- 12001 Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. Brit J Urol Int 88:231–235., , , , ,
- 22001 Biochemical markers for the detection of bone metastasis in patients with prostate cancer: Diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19:45–51., , , , ,
- 32001 Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166:1106–1110.,
- 41983 Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918–924., , , , ,
- 51991 Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68:74–80., ,
- 61994 Bone metastases: Improving the therapeutic index. Semin Oncol 21:630–656.,
- 72001 Concordance between bone histology and technitium 99 methylene diophosphonate bone scan in advanced prostate cancer patients with special reference to bisphosphonate treatment. Cancer Res 42:793., , , , , ,
- 82000 Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632–637., , , , , , ,
- 92001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235–1244., , , , , , , , ,
- 102001 Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18–24., , , ,
- 111998 Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 18:297–305., ,
- 122002 Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94:17–25., , , , , , , , ,
- 131998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453–13458., , , , , , , ,
- 141997 Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59:63–88., ,
- 151998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:32347–32352., , , , , , , ,
- 161995 Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26:171–178., , , , ,
- 172001 An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61:3493–3500.,
- 181994 Immunohistochemical analysis of cathepsins D. B, and L in human breast cancer. Hum Pathol 25:857–862., , , , ,
- 191998 Cathepsin B and human tumor progression. Biol Chem 379:113–123., ,
- 201998 Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 25:1887–1894., , , , , , ,
- 211999 Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues. Arthritis Rheum 42:1588–1593., , ,
- 221997 Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20:81–86., , , , , ,
- 231999 Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 20:612–619., , , , , , , ,
- 241997 The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386–5390., , , , , , , , ,
- 252000 Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation. Mol Med 6:648–659., ,
- 262000 Cathepsin K expression in human lung. Adv Exp Med Biol 477:281–286., , , , , , , , ,
- 272000 Cathepsin K in thyroid epithelial cells: Sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 113:4487–4498., , ,
- 282001 Expression patterns of cathepsins B. H, K, L and S in the human endometrium. Mol Hum Reprod 7:73–78., , , ,
- 292001 Differential expression patterns of cathepsins B. H, K, L and S in the mouse ovary. Mol Hum Reprod 7:27–34., , ,
- 301997 Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem 43:443–452., , ,
- 311996 Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol Pharm Bull 19:1026–1031., , , , , ,
- 321996 Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511–12516., , , , , , , , , , ,
- 332000 Proteinase expression during differentiation of human osteoclasts in vitro. J Cell Biochem 78:627–637., , , ,
- 342000 Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181–186., , , , ,
- 352002 Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952–1956.,
- 361991 Localization of type IV collagen in the basement membranes of human prostate and lymph nodes by immunoperoxidase and immuno alkaline phosphatase. Prostate 18:93–104., , , , , ,
- 371994 Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem 19:232–237., , , ,
- 381989 Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate. Prostate 15:299–313., , , , , , , ,
- 391995 Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146:1498–1507., , , , ,
- 402001 Changes in collagen metabolism in prostate cancer: a host response that may alter progression. J Urol 166:1698–1701., , ,
- 412001 Plasma membrane association of cathepsin B in human prostate cancer: Biochemical and immunogold electron microscopic analysis. Prostate 49:172–184., , , ,
- 422002 Analysis of a truncated form of cathepsin H in human prostate tumor cells. J Biol Chem 277:11533–11538., , , ,
- 432001 Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95:51–55., , , , , , , , ,
- 441999 Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35:138–144., , , , , , ,
- 452002 Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 50:38–45., , , , , , , ,
- 462001 Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 93:507–515., , , , ,
- 472000 Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248–1253., , , , , , , , ,
- 482001 Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187–192.
- 492001 Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181–185., , ,
- 502001 Cysteine protease and cysteine protease inhibitor expression in prostate cancer cell lines. Cancer Res 42:403., , , ,
- 512002 Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52:20–33., , , , , , ,
- 521994 Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 54:3300–3304., , , ,
- 532001 Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611–616., , , , , ,
- 542001 Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49:267–277., , , , , , ,
- 551994 Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines. Urology 43:675–679., , , , ,